As per Data Bridge Market Research analysis, the discovery CRO market was valued at USD 17.86 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 7.80% from 2026 to 2033.
The market is experiencing consistent growth driven by increasing outsourcing of drug discovery activities by pharmaceutical and biotechnology companies, rising R&D expenditure, growing complexity of drug development processes, and increasing demand for specialized discovery services including target identification, hit discovery, lead optimization, and preclinical research support.
The increasing number of drug development programs globally, combined with the need to reduce research timelines and development costs, is compelling pharmaceutical companies and biotechnology organizations to adopt specialized discovery CRO solutions. Integrated CRO platforms offering medicinal chemistry, biology services, assay development, screening, and drug metabolism and pharmacokinetics (DMPK) services are supporting faster and more efficient drug discovery workflows while enabling access to advanced technologies and scientific expertise.